Improving solubility and oral bioavailability of a novel antimalarial prodrug: comparing spray-dried dispersions with self-emulsifying drug delivery systems.


Journal

Pharmaceutical development and technology
ISSN: 1097-9867
Titre abrégé: Pharm Dev Technol
Pays: England
ID NLM: 9610932

Informations de publication

Date de publication:
Jun 2020
Historique:
pubmed: 8 2 2020
medline: 15 1 2021
entrez: 8 2 2020
Statut: ppublish

Résumé

To improve the solubility and oral bioavailability of a novel antimalarial agent ELQ-331(a prodrug of ELQ-300), spray-dried dispersions (SDD) and a self-emulsifying drug delivery system (SEDDS) were developed. SDD were prepared with polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus

Identifiants

pubmed: 32031478
doi: 10.1080/10837450.2020.1725893
pmc: PMC8120996
mid: NIHMS1693132
doi:

Substances chimiques

6-Chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinolin-4(1H)-one 0
Antimalarials 0
Emulsions 0
Excipients 0
Polyvinyls 0
Prodrugs 0
Quinolones 0
polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 0
Polyethylene Glycols 3WJQ0SDW1A

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

625-639

Subventions

Organisme : BLRD VA
ID : IK6 BX004857
Pays : United States
Organisme : BLRD VA
ID : I01 BX003312
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI100569
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI141412
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI100569
Pays : United States

Références

Biomed Pharmacother. 2004 Apr;58(3):173-82
pubmed: 15082340
Adv Drug Deliv Rev. 2012 May 1;64(6):480-95
pubmed: 22265844
Chem Pharm Bull (Tokyo). 2014;62(6):545-51
pubmed: 24881660
Pharm Res. 1999 Dec;16(12):1812-7
pubmed: 10644067
Pharm Res. 1989 Jan;6(1):40-3
pubmed: 2717516
Int J Pharm. 2004 Apr 15;274(1-2):65-73
pubmed: 15072783
AAPS PharmSciTech. 2004 Jul 27;5(3):e45
pubmed: 15760078
Exp Parasitol. 2011 Feb;127(2):545-51
pubmed: 21040724
J Med Chem. 2014 May 8;57(9):3818-34
pubmed: 24720377
Adv Drug Deliv Rev. 2016 May 1;100:27-50
pubmed: 26705850
J Pharm Sci. 1971 Sep;60(9):1281-302
pubmed: 4935981
Expert Opin Drug Deliv. 2016 Dec;13(12):1681-1694
pubmed: 27267583
Mol Pharm. 2011 Oct 3;8(5):1867-76
pubmed: 21846121
J Pharm Sci. 2012 Jan;101(1):214-22
pubmed: 21918988
Yao Xue Xue Bao. 2009 Jun;44(6):658-66
pubmed: 19806900
J Pharmacol Exp Ther. 1997 Aug;282(2):585-90
pubmed: 9262318
Int J Pharm. 2002 Jan 14;231(2):131-44
pubmed: 11755266
J Pharm Sci. 2016 Sep;105(9):2527-2544
pubmed: 26886314
Pharm Res. 1995 Nov;12(11):1561-72
pubmed: 8592652
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337450
Mol Pharm. 2008 Nov-Dec;5(6):1003-19
pubmed: 19040386
Drug Discov Today. 2007 Dec;12(23-24):1068-75
pubmed: 18061887
Sci Transl Med. 2013 Mar 20;5(177):177ra37
pubmed: 23515079
J Am Chem Soc. 2009 Dec 2;131(47):17048-9
pubmed: 19894718
Eur J Pharm Biopharm. 2000 Jul;50(1):47-60
pubmed: 10840192
J Adv Pharm Technol Res. 2011 Jan;2(1):9-16
pubmed: 22171286
J Pharm Sci. 1985 Apr;74(4):416-21
pubmed: 3999002
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27919897
Nat Rev Drug Discov. 2007 Mar;6(3):231-48
pubmed: 17330072
Iran J Pharm Res. 2015 Winter;14(1):35-50
pubmed: 25561910
J Pharmacol Exp Ther. 1995 Nov;275(2):958-64
pubmed: 7473188
Science. 2008 Apr 18;320(5874):330-4
pubmed: 18420924
Eur J Pharm Sci. 2005 Oct;26(2):219-30
pubmed: 16087324
ACS Infect Dis. 2017 Oct 13;3(10):728-735
pubmed: 28927276
Int J Pharm. 2003 Nov 28;267(1-2):79-91
pubmed: 14602386
Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S93-8
pubmed: 11033431
Mol Pharm. 2012 Jul 2;9(7):2009-16
pubmed: 22632106
J Control Release. 2006 Mar 10;111(1-2):56-64
pubmed: 16410029
Drug Dev Ind Pharm. 2013 Oct;39(10):1562-72
pubmed: 23030270
Anticancer Res. 1998 Jul-Aug;18(4C):3005-9
pubmed: 9713500
Sci Pharm. 2012 Dec;80(4):1027-43
pubmed: 23264948
Mol Pharm. 2018 May 7;15(5):2045-2053
pubmed: 29641898
AAPS J. 2007 Oct 26;9(3):E344-52
pubmed: 18170981
Int J Pharm. 2005 Sep 14;301(1-2):209-16
pubmed: 16046087
Int J Pharm. 1999 Oct 5;187(2):209-18
pubmed: 10502627
N Engl J Med. 2011 Sep 22;365(12):1073-5
pubmed: 21992120
Eur J Pharm Sci. 2005 Apr;24(5):477-86
pubmed: 15784337
J Pharm Sci. 1998 Jul;87(7):891-900
pubmed: 9649360
Chem Pharm Bull (Tokyo). 2000 May;48(5):646-50
pubmed: 10823700
Pharm Res. 1996 Apr;13(4):528-34
pubmed: 8710741

Auteurs

Suresh Potharaju (S)

Biosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.

Shravan Kumar Mutyam (SK)

Biosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.

Mingtao Liu (M)

Biosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.

Carol Green (C)

Biosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.

Lisa Frueh (L)

Experimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.

Aaron Nilsen (A)

Experimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.

Sovitj Pou (S)

Experimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.

Rolf Winter (R)

Experimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.

Michael K Riscoe (MK)

Experimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.

Gita Shankar (G)

Biosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH